| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, 3075 EA Rotterdam, the Netherlands [R. H. J. M., J. V., A. S.]; Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110 [S. M., H. L. M.]; Department of Pharmaceutical Biosciences, Uppsala University, SE-751 24 Uppsala, Sweden [M. O. K., R. X.]; and Division of Experimental Therapeutics, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 [S. D. B.]
ABSTRACT
Purpose: The purpose was to explore the relationships between irinotecan disposition and allelic variants of genes coding for adenosine triphosphate binding cassette transporters and enzymes of putative relevance for irinotecan.
Experimental Design: Irinotecan was administered to 65 cancer patients as a 90-min infusion (dose, 200–350 mg/m2), and pharmacokinetic data were obtained during the first cycle. All patients were genotyped for variants in genes encoding MDR1 P-glycoprotein (ABCB1), multidrug resistance-associated proteins MRP-1 (ABCC1) and MRP-2 (canalicular multispecific organic anion transporter; ABCC2), breast cancer resistance protein (ABCG2), carboxylesterases (CES1, CES2), cytochrome P450 isozymes (CYP3A4, CYP3A5), UDP glucuronosyltransferase (UGT1A1), and a DNA-repair enzyme (XRCC1), which was included as a nonmechanistic control.
Results: Eighteen genetic variants were found in nine genes of putative importance for irinotecan disposition. The homozygous T allele of the ABCB1 1236C>T polymorphism was associated with significantly increased exposure to irinotecan (P = 0.038) and its active metabolite SN-38 (P = 0.031). Pharmacokinetic parameters were not related to any of the other multiple variant genotypes, possibly because of the low allele frequency. The extent of SN-38 glucuronidation was slightly impaired in homozygous variants of UGT1A1*28, although differences were not statistically significant (P = 0.22).
Conclusions: It is concluded that genotyping for ABCB1 1236C>T may be one of the factors assisting with dose optimization of irinotecan chemotherapy in cancer patients. Additional investigation is required to confirm these findings in a larger population and to assess relationships between irinotecan disposition and the rare variant genotypes, especially in other ethnic groups.
This article has been cited by other articles:
|
|
 |
|
  J. A. Williams, T. Andersson, T. B. Andersson, R. Blanchard, M. O. Behm, N. Cohen, T. Edeki, M. Franc, K. M. Hillgren, K. J. Johnson, et al. PhRMA White Paper on ADME Pharmacogenomics J. Clin. Pharmacol., July 1, 2008; 48(7): 849 - 889. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Poonkuzhali, J. Lamba, S. Strom, A. Sparreboom, K. Thummel, P. Watkins, and E. Schuetz Association of Breast Cancer Resistance Protein/ABCG2 Phenotypes and Novel Promoter and Intron 1 Single Nucleotide Polymorphisms Drug Metab. Dispos., April 1, 2008; 36(4): 780 - 795. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Marchetti, R. Mazzanti, J. H. Beijnen, and J. H. M. Schellens Concise Review: Clinical Relevance of Drug Drug and Herb Drug Interactions Mediated by the ABC Transporter ABCB1 (MDR1, P-glycoprotein) Oncologist, August 1, 2007; 12(8): 927 - 941. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Wang, J. Wang, E. Tantoso, B. Wang, A. Y.P. Tai, L. L.P.J. Ooi, S. S. Chong, and C. G.L. Lee Signatures of recent positive selection at the ATP-binding cassette drug transporter superfamily gene loci Hum. Mol. Genet., June 1, 2007; 16(11): 1367 - 1380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-F. Cote, S. Kirzin, A. Kramar, J.-F. Mosnier, M.-D. Diebold, I. Soubeyran, A.-S. Thirouard, J. Selves, P. Laurent-Puig, and M. Ychou UGT1A1 Polymorphism Can Predict Hematologic Toxicity in Patients Treated with Irinotecan Clin. Cancer Res., June 1, 2007; 13(11): 3269 - 3275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Ramchandani, Y. Wang, B. P. Booth, A. Ibrahim, J. R. Johnson, A. Rahman, M. Mehta, F. Innocenti, M. J. Ratain, and J. V. S. Gobburu The Role of SN-38 Exposure, UGT1A1*28 Polymorphism, and Baseline Bilirubin Level in Predicting Severe Irinotecan Toxicity J. Clin. Pharmacol., January 1, 2007; 47(1): 78 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Hahn, J. J. Wolff, and J. M. Kolesar Pharmacogenetics and irinotecan therapy Am. J. Health Syst. Pharm., November 15, 2006; 63(22): 2211 - 2217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M. Hahn, S. Marsh, W. Fisher, R. Langdon, R. Zon, M. Browning, C. S. Johnson, T. J. Scott-Horton, L. Li, H. L. McLeod, et al. Hoosier Oncology Group Randomized Phase II Study of Docetaxel, Vinorelbine, and Estramustine in Combination in Hormone-Refractory Prostate Cancer with Pharmacogenetic Survival Analysis. Clin. Cancer Res., October 15, 2006; 12(20): 6094 - 6099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Bosch, A. D.R. Huitema, V. D. Doodeman, R. Jansen, E. Witteveen, W. M. Smit, R. L. Jansen, C. M. van Herpen, M. Soesan, J. H. Beijnen, et al. Pharmacogenetic Screening of CYP3A and ABCB1 in Relation to Population Pharmacokinetics of Docetaxel. Clin. Cancer Res., October 1, 2006; 12(19): 5786 - 5793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Michael, M. Thompson, R. J. Hicks, P. L. Mitchell, A. Ellis, A. D. Milner, J. Di Iulio, A. M. Scott, V. Gurtler, J. M. Hoskins, et al. Relationship of Hepatic Functional Imaging to Irinotecan Pharmacokinetics and Genetic Parameters of Drug Elimination J. Clin. Oncol., September 10, 2006; 24(26): 4228 - 4235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-Y. Han, H.-S. Lim, E. S. Shin, Y.-K. Yoo, Y. H. Park, J.-E. Lee, I.-J. Jang, D. Ho Lee, and J. Soo Lee Comprehensive Analysis of UGT1A Polymorphisms Predictive for Pharmacokinetics and Treatment Outcome in Patients With Non-Small-Cell Lung Cancer Treated With Irinotecan and Cisplatin J. Clin. Oncol., May 20, 2006; 24(15): 2237 - 2244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-i. Fujita, Y. Ando, M. Narabayashi, T. Miya, F. Nagashima, W. Yamamoto, K. Kodama, K. Araki, H. Endo, and Y. Sasaki GEFITINIB (IRESSA) INHIBITS THE CYP3A4-MEDIATED FORMATION OF 7-ETHYL-10-(4-AMINO-1-PIPERIDINO)CARBONYLOXYCAMPTOTHECIN BUT ACTIVATES THAT OF 7-ETHYL-10-[4-N-(5-AMINOPENTANOIC ACID)-1-PIPERIDINO]CARBONYLOXYCAMPTOTHECIN FROM IRINOTECAN Drug Metab. Dispos., December 1, 2005; 33(12): 1785 - 1790. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Henningsson, S. Marsh, W. J. Loos, M. O. Karlsson, A. Garsa, K. Mross, S. Mielke, L. Vigano, A. Locatelli, J. Verweij, et al. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 Polymorphisms with the Pharmacokinetics of Paclitaxel Clin. Cancer Res., November 15, 2005; 11(22): 8097 - 8104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Sadee and Z. Dai Pharmacogenetics/genomics and personalized medicine Hum. Mol. Genet., October 15, 2005; 14(suppl_2): R207 - R214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Cecchin, G. Corona, S. Masier, P. Biason, G. Cattarossi, S. Frustaci, A. Buonadonna, A. Colussi, and G. Toffoli Carboxylesterase Isoform 2 mRNA Expression in Peripheral Blood Mononuclear Cells Is a Predictive Marker of the Irinotecan to SN38 Activation Step in Colorectal Cancer Patients Clin. Cancer Res., October 1, 2005; 11(19): 6901 - 6907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Wang, B. Wang, K. Tang, E. J.D. Lee, S. S. Chong, and C. G.L. Lee A functional polymorphism within the MRP1 gene locus identified through its genomic signature of positive selection Hum. Mol. Genet., July 15, 2005; 14(14): 2075 - 2087. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Nozawa, H. Minami, S. Sugiura, A. Tsuji, and I. Tamai ROLE OF ORGANIC ANION TRANSPORTER OATP1B1 (OATP-C) IN HEPATIC UPTAKE OF IRINOTECAN AND ITS ACTIVE METABOLITE, 7-ETHYL-10-HYDROXYCAMPTOTHECIN: IN VITRO EVIDENCE AND EFFECT OF SINGLE NUCLEOTIDE POLYMORPHISMS Drug Metab. Dispos., March 1, 2005; 33(3): 434 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Soepenberg, H. Dumez, J. Verweij, F. A. de Jong, M. J.A. de Jonge, J. Thomas, F. A.L.M. Eskens, R. H.N. van Schaik, J. Selleslach, J. ter Steeg, et al. Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors Clin. Cancer Res., February 15, 2005; 11(4): 1504 - 1511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Lee, A. C. Lockhart, R. B. Kim, and M. L. Rothenberg Cancer Pharmacogenomics: Powerful Tools in Cancer Chemotherapy and Drug Development Oncologist, February 1, 2005; 10(2): 104 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. de Jong, S. Marsh, R. H. J. Mathijssen, C. King, J. Verweij, A. Sparreboom, and H. L. McLeod ABCG2 Pharmacogenetics: Ethnic Differences in Allele Frequency and Assessment of Influence on Irinotecan Disposition Clin. Cancer Res., September 1, 2004; 10(17): 5889 - 5894. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Paoluzzi, A. S. Singh, D. K. Price, R. Danesi, R. H. J. Mathijssen, J. Verweij, W. D. Figg, and A. Sparreboom Influence of Genetic Variants in UGT1A1 and UGT1A9 on the In Vivo Glucuronidation of SN-38 J. Clin. Pharmacol., August 1, 2004; 44(8): 854 - 860. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Rouits, M. Boisdron-Celle, A. Dumont, O. Guerin, A. Morel, and E. Gamelin Relevance of Different UGT1A1 Polymorphisms in Irinotecan-Induced Toxicity: A Molecular and Clinical Study of 75 Patients Clin. Cancer Res., August 1, 2004; 10(15): 5151 - 5159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. de Jong, R. H. J. Mathijssen, R. Xie, J. Verweij, and A. Sparreboom Flat-Fixed Dosing of Irinotecan: Influence on Pharmacokinetic and Pharmacodynamic Variability Clin. Cancer Res., June 15, 2004; 10(12): 4068 - 4071. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. McLeod and J. W. Watters Irinotecan Pharmacogenetics: Is It Time to Intervene? J. Clin. Oncol., April 15, 2004; 22(8): 1356 - 1359. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
